Pharma Mar (OTCMKTS:PHMMF) Reaches New 12-Month Low – What’s Next?
by Mitch Edgeman · The Markets DailyPharma Mar (OTCMKTS:PHMMF – Get Free Report) reached a new 52-week low on Friday . The company traded as low as $79.00 and last traded at $79.00, with a volume of 100 shares trading hands. The stock had previously closed at $100.60.
Analyst Ratings Changes
Separately, BTIG Research initiated coverage on Pharma Mar in a report on Thursday, April 23rd. They issued a “buy” rating on the stock. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Pharma Mar has an average rating of “Buy”.
Get Our Latest Analysis on PHMMF
Pharma Mar Trading Down 21.0%
The company has a fifty day moving average price of $105.26 and a 200 day moving average price of $94.59. The company has a quick ratio of 2.44, a current ratio of 3.02 and a debt-to-equity ratio of 0.14.
About Pharma Mar
PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.
The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.